1 |
Krause D. C., and D. Taylor-Robinson. 1992. Mycoplasma which infect humans. pp417-444, In Maniloff J. (ed), Mycoplasmas, ASM, Washington
|
2 |
Roberts M. C., L. A. Koutsky, K. K. Holmes, D. J. LeBlanc, and G. E. Kenny. 1985. Tetracycline-resistant Mycoplasma hominis strains contain streptococcal tetM sequences. Antimicrob. Agents Chemother, 28, 141-143
DOI
ScienceOn
|
3 |
Okazaki, N., M. Narita, S. Yamada, K. Izumikawa, M. Umetsu, T. Kenri, Y. Sasaki, Y. Arakawa, and T. Sasaki. 2001. Characteristics of macrolide-resistant M. pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol. Immunol. 45, 617-620
DOI
|
4 |
Park I. D., K. H. Kim, M. W. Chang, and H. S. Park. 1992. Distribution of tetM gene in the tetracycline resistant Bacteria. J. Korean Soc. Microbiol. 27, 59-72
|
5 |
Arai, S. and Y. Tokitsu. 1995. Antimycoplasmacidal activity of new quinolones in vitro and in vivo. Jap. J. Mycoplasmol. 21, 37-38
|
6 |
Hamamoto K., T. Shimizu, N. Fujimoto, Y. Zhang, and S. Arai. 2001. In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 4,: 1908-1910
|
7 |
Duffy L. B., D. M. Crabb, X. Bing, and K. B. Waites. 2003. Bactericidal activity of levofloxacin against Mycoplasma pneumoniae. J. Antimicrob. Chemother. 52, 527-528
DOI
ScienceOn
|
8 |
Matsuoka, M., M. Narita, N. Okazki, H. Ohya, T. Yamazaki, K. Ouchi, I. Suzuki, and T. Sasaki. 2004. Characterization and molecular analysis of macrolide- resistant M. pneumoniae clinical isolates obtained in Japan. Antimicrob. Agents Chemother. 48, 4624-4630
DOI
ScienceOn
|
9 |
Waites K. B., D. M. Crabb, and L. B. Duffy. 2003. In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas. Antimicrob. Agents Chemother. 47, 39-42
DOI
|
10 |
Weisblum, B. 1995. Erythromycin resistance by ribosome modification. Antimicrob. Agents Chemother. 39, 577-585
DOI
ScienceOn
|
11 |
Pereyre, S., C. Guyot, H. Renaudin, A. Charron, C. Bebear, and C. M. Bebear. 2004. In vitro selection and characterization of resistance to macrolides and related antibiotics in M. pneumoniae. Antimicrob. Agents Chemother. 48, 460-465
DOI
|
12 |
Shames J. M., R. B. George, W. B. Holliday, J. R. Rasch, and W. J. Mogabgab. 1970. Comparison of antibiotics in the treatment of mycoplasmal pneumonia. Arch. Intern. Med. 125, 680-684
DOI
|
13 |
Suyama, N., K. Ishida, M. Kaku, K. Izumikawa, and K. Hara. 1995. Therapeutic activites of macrolides against M. pneumoniae infection. Jap. J. Mycoplasmol. 21, 39-40
|
14 |
Izumikawa K., Y. Hirakata, T. Yamaguchi, R. Yoshida, H. Tanaka, H. Takemura, S. Maesaki, K. Tomono, M. Kaku, K. I. Izumikawa, S. Kamihira, and S. Kohono. 1998. In vitro activities of quinupristin-dalfopristin and the strteptogramin RPR 106972 against M. pneumoniae. Antimicrob. Agents Chemother. 42, 698-699
|
15 |
Chang M. W., K. H. Kim, I. D. Park, G. Y. Song, S. W. Kim, M. H. Joh, and C. E. Choi. 2005. Isolation of Mycoplasma pneumoniae and antimicrobial susceptibilities of the isolates(III). J. Life Sci. 15, 479-485
과학기술학회마을
DOI
ScienceOn
|
16 |
Vester, B. and S. Douthwaite. 2001. Macrolide resistance conferred by base substitution in 23S rRNA. Antimicrob. Agents Chemother. 45, 1-12
DOI
|
17 |
Waites, K. B., L. B. Duffy, T. Schmid, D. Carb, M. S. Pate, and G. H. Cassell. 1991. In vitro susceptibilities of Mycoplasma pneumoniae, M. hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391. Antimicrob. Agents Chemother. 35, 1181-1185
DOI
ScienceOn
|
18 |
Waites K. B., D. M. Crabb, and L. B. Duffy. 2003. Inhibitory and bactericidal activities of gemifloxacin and other antimicrobials against Mycoplasma pneumoniae. Int. J. Antimicrob. Agents. 21, 574-577
DOI
ScienceOn
|
19 |
Waites K. B., D. M. Crabb, X. Bing, and L. B. Duffy. 2003. In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobials against human mycoplasmas and ureaplasmas. Antimicrob. Agents Chemother. 47, 161-165
DOI
|
20 |
Kaku, M., K. Ishida, K. Irifune, R. Mizukane, H. Takemura, R. Yoshida, and et al. 1994. In vitro activities of sparfloxacin against M. pneumoniae. Antimicrob. Agents Chemother. 38, 738-741
DOI
ScienceOn
|
21 |
Kenny, G. E. and F. D. Cartwright. 1994. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to new glycycyclines in comparison with those to older tetracyclines. Antimicrob. Agents Chemother. 38, 2628-2632
DOI
ScienceOn
|
22 |
Niitu Y., S. Hasegawa , T. Suetake, H. Kubota, S. Komatu, and M. Horikawa. 1970. Resistance of Mycoplasma pneumoniae to erythromycin and other antibiotics. J. Pediatr. 76, 434-443
|
23 |
Pereyre, S., P. Gonzalez, B. de Barbeyrac, A. Darnige, H. Renaudin, A. Charron, S. Raherison, and C. M. Bebear, 2002. Mutation in 23S rRNA account for intrindic resistance to macrolides in M. hominis and M. fermentans and for acquired resistance to macrolides in M. hominis. Antimicrob. Agents Chemother. 46, 3142-3150
DOI
|
24 |
Kenny, G. E. and F. D. Cartwright, 1996. Susceptibilities of M. pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to new quinolone, trovafloxacin(CP-99219). Antimicrob. Agents Chemother. 40, 1048-1049
|
25 |
Lucier, T. S., K. Heitzman, S. K. Liu, and P. C. Hu. 1995. Transition mutations in the 23S rRNA of erythromycin-resistant isolates of M. pneumoniae. Antimicrob. Agents Chemother. 39, 2770-2773
DOI
ScienceOn
|
26 |
MacGowan A. P. 1999. Moxifloxacin(Bay 12-8039): a new methoxy quinolone antibacterial. Expert. Opin. Investig. Drugs. 8, 181-199
DOI
ScienceOn
|
27 |
Morozumi M., K. Hasegawa, R. Kobayashi, N. Inoue, S. Iwata, H. Kuroki, N. Kawamura, E. Nakayama, T. Tajima, K. Shimizu, and K. Ubukata. 2005. Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation. Antimicrob. Agents Chemother. 49, 2302-2306
DOI
ScienceOn
|
28 |
Blanchard A., and C. Bebear. 2002. Mycoplasmas of human, pp 45-71, In Razin S, and Hermann R (ed), Molecular biology and pathogenicity of mycoplasma. Kluwer Academic Pub., New York
|
29 |
Cassell, G. H., W. A. Clyde, and J. K. Davis. 1985. Mycoplasmal respiratory infections. pp. 65-106, In The Mycoplasmas Vol. IV, S. Razin and M. F. Barile (Ed), Academic Press, New York
|
30 |
Chang M. W., K. H. Kim, I. D. Park, and M. H. Joh. 1995. Detection of Mycoplasma pneumoniae in clinical specimens of patients by polymerase chain reaction and culture method. J. Korean Soc. Microbiol. 30, 517-525
|
31 |
Chang M. W., I. D. Park, K. H. Kim, G. Y. Song, and S. W. Kim. 2005. Tetracycline and erythromycin resistant mutans of the Mycoplasma pneumoniae isolated from patients with resipratory diseases. J. Life Sci. 15, 863-870
과학기술학회마을
DOI
ScienceOn
|
32 |
Hempstead P. G. 1990. An improved method for the rapid isolation of chromosomal DNA from Mycoplasma spp. Can. J. Microbiol. 36, 59-64
DOI
ScienceOn
|
33 |
Ford O. K., and J. R. Smith. 1974. Nonspecific urethritis associated with a tetracycline- resistant T-mycoplasama. Br. J. Vener Dis. 50, 373-377
|
34 |
Foy H., G. E. Kenny, M. K. Cooney, and I. D. Allen. 1979. Long-term epidemiology of infections with Mycoplasma pneumoniae. J. Infect. Dis. 139, 681-687
DOI
ScienceOn
|
35 |
Furneri, P. M., G. Rappazzo, M. P. Musumarra, P. Dipietro, L. S. Catania, and L. S. Roccasalva. 2001. Two new point mutations at A2062 associated with resistance to 16-membered macrolide antibiotics in mutant strains of M. hominis. Antimicrob. Agents Chemother. 45, 2958-2960
DOI
ScienceOn
|
36 |
Arai, S., Y. Gohara, K. Kuwano, and T. Kawashima. 1992. Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae. Antimicrobial Agents Chemother. 36, 1322-1324
DOI
ScienceOn
|
37 |
Yamaguchi, T., Y. Hirakata, K. Izumikawa, Y. Miyazaki, S. Maesaki, K. Tomono, Y. Yamada, S. Kamihira, and S. Kohno. 2000. In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of M. pneumoniae in Japan. Antimicrob. Agents chemother. 44, 1381-1382
DOI
|
38 |
Chang M. W., K. H. Kim, I. D. Park, K. H. Kang, E. H. Kong, M. H. Joh, G. Y. Song, and S. W. Kim. 2003. Rapid detection of Mycoplasma pneumoniae and antimicrobial susceptibilities of the M. pneumoniae isolates. J. Bacteriol. Virol. 33, 183-191
|
39 |
Critchley I. A., M. E. Jones, P. D. Heinze, D. Hubbard, H. D. Engler, A. T. Evangelista, C. Thornsberry, J. A. Karlowsky, and D. F. Sajm. 2002. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumonphila, Mycoplasma pneumoniae and Chlamydia pneumoniae from north America and Europe. Clin. Microbiol. Infect. 8, 214-221
DOI
ScienceOn
|
40 |
Smith R. P., A. L. Baltch, W. J. Ritz, A. N. Carpenter, T. A. Halse, and L. H. Bopp. 2004. In vitro activities of garenoxacin and levofloxacin against Chlamydia pneumoniae are not affected by presence of Mycoplasma DNA. Antimicrb. Agents Chemother. 48, 2081-2084
DOI
ScienceOn
|
41 |
Kapusnik-Uner J. E., M. A. Sande, H. F. Chambers. 1996. Antimicrobial agents, tetracycline, chloramphenicol, erythromycin, and miscellaneous antimicrobial agents, pp1123-1153, In Goodman & Gilman,s The pharmacological basis of therapeutics, 9th(ed), McGraw-Hill, New York
|